Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05078385 · ClinicalTrials.gov registry record · Phase 1
Safety of Extracellular Vesicles for Burn Wounds
A Phase 1 study of Burns, sponsored by Aegle Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 2
- Study locations
NCT05078385 is a Phase 1 study of Burns that has completed, run by Aegle Therapeutics. The registered enrollment target is 1 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05078385, a Phase 1 study of Burns, has completed, sponsored by Aegle Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 2
- Study locations
Study Summary
Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.
Conditions Studied
Interventions
- DRUG AGLE-102
Study Locations (2)
Florida
- Ryder Trauma Center - Miami
North Carolina
- North Carolina Jaycee Burn Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-08-10 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05078385
The ClinicalTrials.gov registry entry for NCT05078385 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 36 other Burns trials with a reported enrollment target (99% lower). The listed sponsor is Aegle Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 1 intervention - of which AGLE-102 is the first listed.
NCT05078385 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05078385 about?
NCT05078385 is a clinical study titled "Safety of Extracellular Vesicles for Burn Wounds". Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.
What is the current status of trial NCT05078385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2023-08-10. Estimated completion is 2024-11-19.
What conditions does trial NCT05078385 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT05078385?
The interventions under investigation include: AGLE-102 (DRUG).
Who is sponsoring clinical trial NCT05078385?
This trial is sponsored by Aegle Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05078385 being conducted?
This trial has 2 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
COMPLETED · Phase 1
-
Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes
COMPLETED · Phase 1
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
-
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
RECRUITING · Phase 4
-
Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.